Literature DB >> 21390504

Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine ("Ecstasy")/polydrug users.

Adrian P Burgess1, Louise Venables, Helena Jones, Rhiannon Edwards, Andrew C Parrott.   

Abstract

OBJECTIVES: Ecstasy is a recreational drug whose active ingredient, 3,4-methylenedioxymethamphetamine (MDMA), acts predominantly on the serotonergic system. Although MDMA is known to be neurotoxic in animals, the long-term effects of recreational Ecstasy use in humans remain controversial but one commonly reported consequence is mild cognitive impairment particularly affecting verbal episodic memory. Although event-related potentials (ERPs) have made significant contributions to our understanding of human memory processes, until now they have not been applied to study the long-term effects of Ecstasy. The aim of this study was to examine the effects of past Ecstasy use on recognition memory for both verbal and non-verbal stimuli using ERPs.
METHODS: We compared the ERPs of 15 Ecstasy/polydrug users with those of 14 cannabis users and 13 non-illicit drug users as controls.
RESULTS: Despite equivalent memory performance, Ecstasy/polydrug users showed an attenuated late positivity over left parietal scalp sites, a component associated with the specific memory process of recollection.
CONCLUSIONS: [corrected] This effect was only found in the word recognition task which is consistent with evidence that left hemisphere cognitive functions are disproportionately affected by Ecstasy, probably because the serotonergic system is laterally asymmetrical. Experimentally, decreasing central serotonergic activity through acute tryptophan depletion also selectively impairs recollection, and this too suggests the importance of the serotonergic system. Overall, our results suggest that Ecstasy users, who also use a wide range of other drugs, show a durable abnormality in a specific ERP component thought to be associated with recollection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390504     DOI: 10.1007/s00213-011-2249-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Short duration power changes in the EEG during recognition memory for words and faces.

Authors:  A P Burgess; J H Gruzelier
Journal:  Psychophysiology       Date:  2000-09       Impact factor: 4.016

Review 2.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

3.  Serotonergic interhemispheric asymmetry: neurochemical and pharmaco-EEG evidence.

Authors:  M Arato; E Frecska; D J Maccrimmon; R Guscott; B Saxena; K Tekes; L Tothfalusi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1991       Impact factor: 5.067

4.  Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.

Authors:  A C Parrott; T Buchanan; A B Scholey; T Heffernan; J Ling; J Rodgers
Journal:  Hum Psychopharmacol       Date:  2002-08       Impact factor: 1.672

5.  The mechansim of auditory evoked EEG responses.

Authors:  B M Sayers; H A Beagley; W R Henshall
Journal:  Nature       Date:  1974-02-15       Impact factor: 49.962

6.  Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.

Authors:  G Hatzidimitriou; U D McCann; G A Ricaurte
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

7.  Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.

Authors:  A C Parrott; R M Milani; R Parmar; J D Turner
Journal:  Psychopharmacology (Berl)       Date:  2001-09-11       Impact factor: 4.530

8.  Daily uplifts, hassles, stresses and cognitive failures: in cigarette smokers, abstaining smokers, and non-smokers.

Authors:  A C Parrott; F J Kaye
Journal:  Behav Pharmacol       Date:  1999-11       Impact factor: 2.293

Review 9.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

10.  Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.

Authors:  Celia J A Morgan; Leslie Muetzelfeldt; H Valerie Curran
Journal:  Addiction       Date:  2009-11-17       Impact factor: 6.526

View more
  5 in total

1.  ERP evidence suggests executive dysfunction in ecstasy polydrug users.

Authors:  C A Roberts; S H Fairclough; J E Fisk; F Tames; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-03-27       Impact factor: 4.530

2.  Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing.

Authors:  Tristan J Watkins; Vidya Raj; Junghee Lee; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Ronald M Salomon; Sohee Park; Margaret M Benningfield; Christina R Di Iorio; Ronald L Cowan
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

3.  MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase.

Authors:  John H Anneken; Jacobi I Cunningham; Stuart A Collins; Bryan K Yamamoto; Gary A Gudelsky
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

4.  Meta-analysis of executive functioning in ecstasy/polydrug users.

Authors:  C A Roberts; A Jones; C Montgomery
Journal:  Psychol Med       Date:  2016-03-11       Impact factor: 7.723

5.  Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study.

Authors:  Daniel Wagner; Simon Tkotz; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Joerg Daumann
Journal:  Front Neurosci       Date:  2015-12-08       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.